Key MessageThe results of this study suggest that *EGFR* mutant subtypes of non-small-cell lung cancer have distinct response to immune checkpoint inhibitors and distinct tumor mutation burdens. This knowledge may be useful in selecting patients with a higher likelihood of response to immunotherapy.

Introduction
============

Epidermal growth factor receptor (*EGFR*) mutant lung cancers represent a distinct subset of non-small-cell lung cancer (NSCLC) with broad molecular and clinical heterogeneity. Recurrent alterations in exons 18--21 are commonly observed \[[@mdz141-B1]\] and most, but not all, confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs) \[[@mdz141-B4]\]. Even the most common EGFR TKI-sensitizing alleles, EGFR L858R (*EGFR^L858R^*) and EGFR exon 19 deletions (*EGFR^Δ19^*), have differences in outcomes with TKIs \[[@mdz141-B7], [@mdz141-B8]\]. Despite initial responsiveness to EGFR TKIs, acquired resistance is routine \[[@mdz141-B4], [@mdz141-B9]\]. The inevitability of resistance has raised hopes of a role for immune checkpoint inhibitors (ICIs), with the potential for more durable responses; however, in contrast to preclinical studies \[[@mdz141-B12]\], clinical evidence suggests that *EGFR* mutant lung cancers rarely derive benefit from treatment with ICIs \[[@mdz141-B13]\]. Rates of positivity for potential predictors of response to ICIs, such as tumor mutation burden (TMB) and concurrent programed death-ligand 1 (PD-L1) plus CD8+ tumor infiltrating lymphocyte expression, are low \[[@mdz141-B17]\]. Yet recent studies have emerged, such as ATLANTIC and IMpower150, that have shown more encouraging results for PD-(L)1 blockade in *EGFR* mutant lung cancers \[[@mdz141-B18], [@mdz141-B19]\].

We hypothesized that the molecularly heterogeneous features of *EGFR* mutant lung cancers may provide insight into the outcomes with ICIs and improve understanding of the determinants of response in these tumors \[[@mdz141-B20]\]. To test this, we established a multi-institutional consortium and examined the molecular and clinical features of 171 *EGFR* mutant lung cancer cases treated with ICIs. A cohort of 212 patients with *EGFR* wild-type NSCLC (previously published) treated with ICIs was used for comparison. Due to limited sequencing data available for ICI-treated *EGFR* mutant cases in this study, we examined a separate cohort of 383 patients with *EGFR* mutant lung cancer (irrespective of treatment history) to examine the relationship between TMB and *EGFR* mutation subtype.

Methods
=======

Cohorts of *EGFR* mutant lung cancers
-------------------------------------

Following IRB approval at each respective institution, patients with *EGFR* mutant lung cancer treated with PD-(L)1 blockade therapy were identified (Yale Cancer Center *n *= 37, Memorial Sloan Kettering Cancer Center *n* = 67, University of California Los Angeles *n* = 35, Dana Farber Cancer Institute *n* = 32). Patients were treated as part of a clinical trial (*n* = 97; 56.7%) or standard-of-care (*n* = 74; 43.3%). Due to the retrospective nature of this study, scan intervals were not uniform between all patients. Patients were included who received anti-PD-(L)1 alone or in combination with anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4), and this treatment was their first exposure to ICIs. In a subset of patients (*n*=15), ICIs were added to continuation of EGFR TKIs at TKI resistance. In *EGFR^L858R^* and *EGFR^Δ19^* cases treated with ICIs before EGFR TKIs, this was due to the absence of information regarding their *EGFR* alteration at the time of treatment (*n* = 7), because the patient was enrolled on a specific clinical trial (*n* = 1) or because the tumor had a baseline *EGFR^T790M^* mutation and was treated with anti-PD-1 plus anti-CTLA-4 therapy (*n* = 1). TMB was studied in data from a cohort of 383 patients with *EGFR* mutant lung cancer, irrespective of treatment exposure, collected from three sources: (i) The Cancer Genome Atlas (*n* = 53), (ii) Yale University (*n* = 17), and (iii) Memorial Sloan Kettering Cancer Center (*n* = 313). TMB was calculated as the total number of non-synonymous mutations divided by the coding region captured for each individual platform (see [supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Results
=======

Distinct *EGFR* subtypes have different outcomes with immune checkpoint blockade
--------------------------------------------------------------------------------

We investigated the impact of varying *EGFR* alleles on outcomes with ICIs (anti-PD-1 or anti-PD-L1, with or without CTLA-4 blockade) in our cohort of 171 *EGFR* mutant cases from four institutions (Table [1](#mdz141-T1){ref-type="table"}), focusing particularly on those 126 patients with tumors with the two most common *EGFR* mutation subtypes \[*EGFR^L858R^*(*n* = 46) or *EGFR^Δ19^* (*n* = 80)\] ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). These cases were evaluated and compared with 212 patients with *EGFR* wild-type (WT) NSCLC treated with ICIs \[[@mdz141-B21]\]. *EGFR^Δ19^*tumors had a significantly lower overall response rate (ORR) compared with *EGFR* WT tumors (5 of 76, 7% versus 47 of 212, 22%, respectively, *P* = 0.002), whereas *EGFR^L858R^*tumors had similar response rates compared with *EGFR* WT tumors (7 of 44, 16%, versus 47 of 212, 22%, respectively, *P* = 0.42) (Figure [1](#mdz141-F1){ref-type="fig"}A). Progression-free survival (PFS) was significantly reduced in both *EGFR^Δ19^*\[(WT versus *EGFR^Δ19^*) HR (hazard ratio) 0.449, 95% CI (confidence interval) 0.338--0.595, log-rank *P* \< 0.001\] and *EGFR^L858R^*\[(WT versus *EGFR^L858R^*) HR 0.578, 95% CI 0.412--0.811, log-rank *P* = 0.001\] subtypes compared with *EGFR* WT (Figure [1](#mdz141-F1){ref-type="fig"}B). Overall survival (OS) in the *EGFR^Δ19^* group was reduced whereas *EGFR^L858R^* tumors had similar OS compared with the *EGFR* WT subgroup (HR 0.69, 95% CI 0.493--0.965, log-rank *P* = 0.03; HR 0.917, 95% CI 0.597--1.409, log-rank *P* = 0.69, respectively) (Figure [1](#mdz141-F1){ref-type="fig"}C). Overall, these data suggest that patients with *EGFR^Δ19^* mutant tumors, in particular, have a significantly reduced benefit of treatment with ICIs.

![Response, progression-free survival, and overall survival of *EGFR^L858R^*and *EGFR^Δ19^* mutant tumors to immune checkpoint blockade. (A) Response rate in tumors with *EGFR^Δ19^* (*n* = 76) or *EGFR^L858R^*(*n* = 44) mutations, and wild-type for *EGFR* (WT) (*n* = 212). Overall response rate is indicated on each bar in white. Statistics were calculated using Fisher's exact test. (B) Progression-free survival in tumors with *EGFR^Δ19^* (*n* = 77) (HR 0.449, 95% CI 0.338--0.595, log-rank *P* \< 0.001) or *EGFR^L858R^*(*n* = 44) (HR 0.578, 95% CI 0.412--0.811, log-rank *P* = 0.001) alterations compared with lung tumors that are *EGFR* wild-type (*n* = 212). (C) Overall survival in tumors with *EGFR^Δ19^* (*n* = 77) (HR 0.69, 95% CI 0.493--0.965, log-rank *P* = 0.03) or *EGFR^L858R^*(*n* = 45) (HR 0.917, 95% CI 0.597--1.409, log-rank *P* = 0.69) alterations compared with lung tumors that are EGFR wild-type (*n* = 212). HR, hazard ratio; CI, confidence interval.](mdz141f1){#mdz141-F1}

###### 

Characteristics of patients with EGFR mutant tumors treated with immune checkpoint inhibitors

  Characteristics                              EGFR^Δ19^ (*n* = 80)   EGFR^L858R^ (*n* = 46)   EGFR^20Ins^ (*n* = 28)   EGFR^G719^ (*n* = 7)   EGFR^L861Q^ (*n* = 5)   EGFR^Other^ (n = 5)   All EGFR cases (*n* = 171)
  ------------------------------------------- ---------------------- ------------------------ ------------------------ ---------------------- ----------------------- --------------------- ----------------------------
  **Smoking**                                                                                                                                                                               
   Ever---no. (%)                                   27 (33.8)               20 (43.5)                10 (35.7)                6 (85.7)                2 (40)                 3 (60)                  68 (39.8)
   Never---no. (%)                                  53 (66.3)               26 (56.5)                18 (64.3)                1 (14.3)                3 (60)                 2 (40)                  103 (60.2)
   Pack-year (median)                                   0                       0                        0                       27                      0                     20                        0
   Pack-year (range)                                  0--40                   0--115                   0--27                   0--40                   0--10                  0--76                    0--115
   Pack-year data---Not available---no. (%)           0 (0)                  1 (2.2)                   0 (0)                   0 (0)                   0 (0)                  0 (0)                   1 (0.6)
  **Prior lines of therapy---no. (%)**                                                                                                                                                      
   0--2 lines                                       29 (36.3)               21 (45.7)                 14 (50)                 4 (57.1)                4 (80)                 3 (60)                  75 (43.9)
   3+ lines                                         51 (63.8)               25 (54.3)                 14 (50)                 3 (42.9)                1 (20)                 2 (40)                  96 (56.1)
  **Drug target---no. (%)**                                                                                                                                                                 
   PD-1                                             66 (82.5)               36 (78.3)                24 (85.7)                7 (100)                 3 (60)                 4 (80)                  140 (81.9)
   PD-L1                                             5 (6.3)                 7 (15.2)                 1 (3.6)                  0 (0)                  1 (20)                 1 (20)                   15 (8.8)
   PD-(L)1 + CTLA-4                                  9 (11.3)                3 (6.5)                  3 (10.7)                 0 (0)                  1 (20)                  0 (0)                   16 (9.4)
  **Progression-free survival (PFS)**                                                                                                                                                       
   Median                                              1.6                     1.9                      1.9                     4.8                     1.3                    2.6                      1.8
   Range                                             0--40.5                0.1--17.7                 0.2--6.4               1.7--37.6               0.9--5.1               1.2--8.7                  0--40.5
   Not available---no. (%)                           3 (3.8)                 2 (4.3)                  2 (7.1)                 1 (14.3)                 0 (0)                  0 (0)                   8 (4.7)
  **Overall survival (OS)**                                                                                                                                                                 
   Median                                              9.4                     12.1                     5.5                     29.0                    5.2                   11.4                      9.4
   Range                                             0.1--71                 0.3--63                 0.6--73.3               2.2--64.8               0.9--13.5              5.2--19.0                0.1--73.3
   Not available---no. (%)                           3 (3.8)                 1 (2.2)                  2 (7.1)                 3 (42.9)                 0 (0)                  0 (0)                   9 (5.3)
  **Best response---no. (%)**                                                                                                                                                               
   Complete/partial response                         5 (6.3)                 7 (15.2)                 3 (10.7)                2 (28.6)                 0 (0)                  0 (0)                   17 (9.9)
   Stable disease                                   13 (16.3)               10 (21.7)                 6 (21.4)                3 (42.9)                1 (20)                 1 (20)                  34 (19.9)
   Progressive disease                              58 (72.5)               27 (58.7)                18 (64.3)                2 (28.6)                4 (80)                 4 (80)                  113 (66.1)
   Not available                                      4 (5)                  2 (4.3)                  1 (3.6)                  0 (0)                   0 (0)                  0 (0)                   7 (4.1)
  **EGFR^T790M^ before ICI---no. (%)**                                                                                                                                                      
   Yes                                              37 (46.3)               17 (37.0)                  0 (0)                  1 (14.3)                 0 (0)                  0 (0)                  55 (32.2)
   No                                               38 (47.5)               29 (63.0)                27 (96.4)                6 (85.7)                5 (100)                5 (100)                 110 (64.3)
   Not available                                     5 (6.3)                  0 (0)                   1 (3.6)                  0 (0)                   0 (0)                  0 (0)                   6 (3.5)
  **EGFR TKI before ICI---no. (%)**                                                                                                                                                         
   Yes                                              74 (92.5)               43 (93.5)                  7 (25)                 4 (57.1)                3 (60)                 2 (40)                  133 (77.8)
   No                                                6 (7.5)                 3 (6.5)                  21 (75)                 3 (42.9)                2 (40)                 3 (60)                  38 (22.2)
   Not available                                      0 (0)                   0 (0)                    0 (0)                   0 (0)                   0 (0)                  0 (0)                    0 (0)
  **PD-L1 expression---no. (%)**                                                                                                                                                            
   \<1%                                             19 (23.8)               11 (23.9)                 6 (21.4)                1 (14.3)                 0 (0)                 1 (20)                  38 (22.2)
   [\>]{.ul}1%                                      10 (12.5)               14 (30.4)                 7 (25.0)                4 (57.1)                 0 (0)                  0 (0)                  35 (20.5)
   Not available                                    51 (63.8)               21 (45.7)                15 (53.6)                2 (28.6)                5 (100)                4 (80)                  98 (57.3)

EGFR TKI, EGFR tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor; PD-L1, programed death-ligand 1.

Clinicopathologic features associated with outcomes in *EGFR* mutant lung cancers
---------------------------------------------------------------------------------

We examined the effect of clinical and pathologic features on response to ICIs in patients with *EGFR^L858R^*and *EGFR^Δ19^* mutant lung cancers. ORR, PFS, and OS were all significantly improved in patients who had received 0--2 prior lines of therapy compared with those with 3+ lines of therapy (ORR: 9 of 47, 19%, versus 3 versus 73, 4%, *P* = 0.01) (PFS: HR 2.267, 95% CI 1.499--3.427, log-rank *P* \< 0.001) (OS: HR 1.845, 95% CI 1.204--2.826, log-rank *P* = 0.004) (Figure [2](#mdz141-F2){ref-type="fig"}A--C). When examined independently, this difference in survival was statistically significant in the *EGFR^Δ19^*cohort but not within the *EGFR^L858R^*group (supplementary Figure S2A--F, available at *Annals of Oncology* online). Smoking history was assessed in patients with *EGFR^L858R^*and *EGFR^Δ19^* mutant lung cancers and positively associated with response rate (*P* = 0.01), but not significantly for PFS or OS outcomes (log-rank *P* = 0.06, *P* = 0.23, respectively). Among patients with tumors resistant to EGFR TKIs, the presence or absence of *EGFR^T790M^* had no impact on the benefit from treatment with ICIs (Figure [2](#mdz141-F2){ref-type="fig"}D--F), irrespective of *EGFR* allele (supplementary Figure S3, available at *Annals of Oncology* online).

![Clinicopathologic features associated with response, progression-free survival, and overall survival of *EGFR^L858R^*and *EGFR^Δ19^* mutant tumors. (A) Response rate of tumors with 0--2 (*n* = 47) or ≥3 (*n* = 73) prior lines of therapy, *P* = 0.01. (B) Progression-free survival with 0--2 (*n* = 46) or ≥3 (*n* = 75) prior lines of therapy (HR 2.267, 95% CI 1.499--3.427, log-rank *P* \< 0.001). (C) Overall survival with 0--2 (*n* = 48) or ≥3 (*n* = 74) prior lines of therapy (HR 1.845, 95% CI 1.204--2.826, log-rank *P* = 0.004). (D) Response rate in tumors harboring *EGFR^T790M^* (T790M+, *n* = 52) or negative for *EGFR^T790M^* (T790M−, *n* = 56) that had prior EGFR tyrosine kinase inhibitor (EGFR TKI) treatment, *P* = 0.21. (E) Progression-free survival in tumors harboring *EGFR^T790M^* (*n* = 52) or negative for *EGFR^T790M^* (*n* = 57) that had prior EGFR TKI treatment (HR 1.348, 95% CI 0.905--2.007, log-rank *P* = 0.15). (F) Overall survival in tumors harboring *EGFR^T790M^* (*n* = 50) or negative for *EGFR^T790M^* (*n* = 60) that had prior EGFR TKI treatment (HR 0.878, 95% CI 0.574--1.343, log-rank *P* = 0.55). (G) Response rate in tumors with \<1% PD-L1 expression (*n* = 28) or ≥1% PD-L1 expression (*n* = 23), *P* \> 0.99. (H) Progression-free survival in tumors with \<1% PD-L1 expression (*n* = 29) or ≥1% PD-L1 expression (*n* = 22) (HR 1.370, 95% CI 0.761--2.466, log-rank *P* = 0.29). (I) Overall survival in tumors with \<1% PD-L1 expression (*n* = 30) or ≥1% PD-L1 expression (*n* = 21) (HR 1.747, 95% CI 0.913--3.342, log-rank *P* = 0.084). Statistical analysis for response rate used Fisher's exact test and statistical analysis for Kaplan--Meier plots used the log-rank test. CI, confidence interval; CR, complete response; HR, hazard ratio; PD-L1, programed death-ligand 1; PR, partial response; SD, stable disease; PD, progressive disease.](mdz141f2){#mdz141-F2}

We also evaluated whether tumor PD-L1 expression was associated with response to ICIs in 73 cases for which staining was available. First, we observed in agreement with published literature \[[@mdz141-B22]\], that there was no difference in PD-L1 expression by *EGFR* allele (supplementary Figure S4A, available at *Annals of Oncology* online). We also noted that PD-L1 expression did not correlate to smoking status in *EGFR* mutant cases. There was no association between the efficacy of ICIs in tumors with ≥1% or \<1% PD-L1 positive staining (ORR: 3 of 23, 13%, versus 4 of 28, 14%, *P* \> 0.99) (PFS: HR 1.370, 95% CI 0.761--2.466, log-rank *P* = 0.29) (OS: HR 1.747, 95% CI 0.913--3.342, log-rank *P* = 0.084) in *EGFR^Δ19^*and *EGFR^L858R^* cases (Figure [2](#mdz141-F2){ref-type="fig"}G--I, supplementary Figure S4B, available at *Annals of Oncology* online), irrespective of EGFR subtype (supplementary Figure S4C--I, available at *Annals of Oncology* online). In *EGFR^Δ19^*and *EGFR^L858R^* tumors, we also noted no association between the efficacy of ICIs and PFS or OS in patients with ≥50% (*n* = 4) or \<50% (*n* = 47) tumor PD-L1 expression, although this comparison was underpowered to make a conclusive association. Due to lack of TMB data in PD-L1 stained cases, we were unable to assess the correlation between TMB and PD-L1 expression, but we acknowledge previous studies in lung cancer showing that PD-L1 expression and TMB are largely uncorrelated \[[@mdz141-B23]\].

*EGFR^Δ19^* mutant lung cancers have a lower tumor mutation burden compared with *EGFR^L858R^* mutant lung cancers
------------------------------------------------------------------------------------------------------------------

Due to the reported association between TMB and response to ICIs, we investigated the TMB across *EGFR* mutation subtypes in lung cancer \[[@mdz141-B26]\]. A lack of sequencing data available from our cohort of 171 *EGFR* mutant tumors treated with immunotherapy led us to compile data from a cohort of 383 sequenced cases of *EGFR* mutant lung cancer from YCC, MSKCC, and TCGA, irrespective of treatment history (Table [2](#mdz141-T2){ref-type="table"}). Across all *EGFR* mutation subtypes, the median TMB was 3.8 non-synonymous mutations/megabase (Mb) with a mean TMB of 5.6 non-synonymous mutations/Mb. This is notably less than the median TMB observed in unselected NSCLC cases (7.4 non-synonymous mutations/Mb by MSK-IMPACT) and the TMB cut-off associated with improved outcomes with immunotherapy in NSCLC (10 non-synonymous mutations/Mb) \[[@mdz141-B21], [@mdz141-B25], [@mdz141-B27]\]. TMB was significantly lower in *EGFR^Δ19^* tumors compared with *EGFR^L858R^* tumors (Figure [3](#mdz141-F3){ref-type="fig"}A, supplementary Figure S5, available at *Annals of Oncology* online). *EGFR^Δ19^*mutant tumors had similar TMB compared with *EGFR^20Ins^* (*P* = 0.35) and *EGFR^L861Q^* tumors, while the TMB in the *EGFR^G719^* group was higher than in *EGFR^Δ19^*tumors (*P* \< 0.001) (Figure [3](#mdz141-F3){ref-type="fig"}A).

![Characterization of *EGFR* allele-specific tumor mutation burden (TMB) and smoking history. (A) TMB was calculated for *EGFR* mutant tumors harboring deletions in exon 19 \[(Δ19) (*n* = 174)\], mutations in exon 21 \[L858R (*n* = 117) and L861Q (*n* = 12)\], insertions in exon 20 \[(20ins) (*n* = 21)\], mutations in exon 18 \[(G719) (*n* = 21)\], or co-mutations at positions G719 and L861Q (*n* = 1). Data were combined from Memorial Sloan Kettering Cancer Center, the Yale Cancer Center, and The Cancer Genome Atlas cohorts. Data were transformed within each cohort to within-cohort percentile rank to permit unified analysis, and median TMB percentile rank is indicated. (B) TMB in *EGFR^L858R^*and *EGFR^Δ19^* mutant tumors from patients with ever (*n* = 99) or never (*n* = 129) smoking status (median 3.8 versus 3.1, *P* = 0.37). (C) Percentage of ever and never smokers within the *EGFR^L858R^*and *EGFR^Δ19^* mutant tumors groups (*P* = 0.14). (D) Pack-years in *EGFR^L858R^*and *EGFR^Δ19^* mutant tumors groups (*P* = 0.58). Statistics were calculated using the Fisher's exact test.](mdz141f3){#mdz141-F3}

###### 

Characteristics of cases included in the tumor mutation burden analysis

  Characteristics                                        EGFR^Δ19^           EGFR^L858R^         EGFR^20Ins^        EGFR^G719^         EGFR^L861Q^       EGFR^G719^ +  EGFR^L861Q^   EGFR^Other^        All EGFR cases
  ------------------------------------------------------ ------------------- ------------------- ------------------ ------------------ ----------------- --------------------------- ------------------ ---------------------
  **Yale Cancer Center**                                                                                                                                                                                
   Number of cases with TMB                              12                  5                   0                  0                  0                 0                           0                  17
   TMB median                                            1.8                 2.5                 n/a                n/a                n/a               n/a                         n/a                2.0
   TMB range                                             0.1--4.1            2.0--4.1            n/a                n/a                n/a               n/a                         n/a                0.1--4.1
   Smoking (ever/never)---no. (%)                        7/5 (58.3/41.7)     4/1 (80/20)         n/a                n/a                n/a               n/a                         n/a                11/6 (64.7/35.3)
   Smoking (ever/never)---data not available---no. (%)   0 (0)               0 (0)               n/a                n/a                n/a               n/a                         n/a                0 (0)
   Smoking (pack-year)---range                           0--120              0--30               n/a                n/a                n/a               n/a                         n/a                0--120
   Smoking (pack-year)---median                          1.5                 10                  n/a                n/a                n/a               n/a                         n/a                4.5
   Smoking (pack-year)---data not available---no. (%)    0 (0)               0 (0)               n/a                n/a                n/a               n/a                         n/a                0 (0)
  **Memorial Sloan Kettering Cancer Center**                                                                                                                                                            
   Number of cases with TMB                              139                 90                  19                 18                 9                 1                           37                 313
   TMB median                                            3.8                 4.7                 2.8                7.3                3.8               5.7                         11.3               4.1
   TMB range                                             0.9--30.2           0.9--17.9           0.9--9.2           2.8--22.6          1.9--10.2         n/a                         0.9--91.8          0.9--91.8
   Smoking (ever/never)---no. (%)                        39/62 (28.1/44.6)   28/40 (31.1/44.4)   3/10 (15.8/52.6)   12/2 (66.7/11.1)   6/2 (66.7/22.2)   1/0 (100/0)                 13/7 (35.1/18.9)   102/123 (32.6/39.3)
   Smoking (ever/never)---data not available---no. (%)   38 (27.3)           22 (24.4)           6 (31.6)           4 (22.2)           1 (11.1)          0 (0)                       17 (45.9)          88 (28.1)
   Smoking (pack-year)---range                           0--99               0--51               0--67.5            0--47.3            0--15             n/a                         0--108             0--108
   Smoking (pack-year)---median                          0                   0                   0                  6.3                6.5               30                          18.5               0
   Smoking (pack-year)---data not available---no. (%)    40 (28.8)           23 (25.6)           6 (31.6)           4 (22.2)           1 (11.1)          0 (0)                       17 (45.9)          91 (29.1)
  **The Cancer Genome Atlas**                                                                                                                                                                           
   Number of cases with TMB                              23                  22                  2                  3                  3                 n/a                         n/a                53
   TMB median                                            1.3                 1.6                 1.5                2.2                3.0               n/a                         n/a                1.4
   TMB range                                             0.7--11.9           0.7--33.9           1.3--1.7           1.0--3.0           1.3--6.3          n/a                         n/a                0.7--33.9
   Smoking (ever/never)---no. (%)                        7/15 (30.4/65.2)    14/6 (63.6/27.3)    0/1 (0/50)         3/0 (100/0)        2/1 (66.7/33.3)   n/a                         n/a                26/23 (49.1/43.4)
   Smoking (ever/never)---data not available---no. (%)   1 (4.3)             2 (9.1)             1 (50)             0 (0)              0 (0)             n/a                         n/a                4 (7.5)
   Smoking (pack-year)---range                           n/a                 n/a                 n/a                n/a                n/a               n/a                         n/a                n/a
   Smoking (pack-year)---median                          n/a                 n/a                 n/a                n/a                n/a               n/a                         n/a                n/a
   Smoking (pack-year)---data not available---no. (%)    n/a                 n/a                 n/a                n/a                n/a               n/a                         n/a                n/a

TMB, tumor mutation burden; n/a, not applicable.

We examined whether smoking history accounted for the differences in TMB in each allele. As expected, there was an association between ever smoking status and higher TMB in all *EGFR* mutant tumors (data not shown), but this was less evident when interrogating only *EGFR^L858R^*and *EGFR^Δ19^*cases (Figure [3](#mdz141-F3){ref-type="fig"}B). Smoking status and pack-years were not different based on the specific *EGFR* allele (Figure [3](#mdz141-F3){ref-type="fig"}C and D) suggesting that there is a difference in TMB between the two most common genetic subtypes of *EGFR* mutant lung cancer that is not simply reflective of differential smoking exposure.

Discussion
==========

Despite the success of EGFR TKIs in *EGFR* mutant lung cancer, all patients eventually develop acquired resistance to these therapies. ICIs have recently emerged as a therapeutic approach in lung cancer with the potential for durable responses but current data suggest that there is limited efficacy in EGFR-driven cancers \[[@mdz141-B13]\]. For example, the ImmunoTarget group assessed response to ICIs across various molecular subgroups of lung cancer and found that tumors with *KRAS*, *BRAF,* or *MET* exon 14 alterations were more likely to derive benefit than cases with *EGFR*, *ALK*, and *RET* alterations \[[@mdz141-B28], [@mdz141-B29], [@mdz141-B30]\]. Yet, some *EGFR* mutant tumors do respond to ICIs \[[@mdz141-B18], [@mdz141-B19]\]. In this study, we assembled the largest cohort of *EGFR* mutant cases treated with ICIs to retrospectively interrogate how genetic, molecular, and clinical factors impact response and survival in this subset of lung cancer. Using this multi-institutional collection of patients, we identified allele-specific differences in response to immune checkpoint inhibition. *EGFR^L858R^* tumors had a similar response rate and OS outcomes to an *EGFR* wild-type lung cancer population, while *EGFR^Δ19^*cases did substantially worse. Of note, we did observe substantially worse PFS between both *EGFR^L858R^*and *EGFR^Δ19^*lung cancer cases compared with *EGFR* wild-type lung cancer cases. The underlying cause for this discrepancy is unknown, but it may be reflective of the variable scanning intervals represented by this multi-institutional cohort composed of both on-trial and off-trial cases. A recent report evaluating outcomes of 27 patients with *EGFR* mutant tumors on ICIs found the best ORR in cases with less common *EGFR* alterations, such as G719X and exon 20 insertions, highlighting potential differences between *EGFR* alleles \[[@mdz141-B31]\].

The outcomes on ICIs contrast with those on EGFR TKIs, where *EGFR^L858R^*tumors have a worse durability of response to EGFR TKIs compared with *EGFR^Δ19^* tumors, highlighting the context specificity of genotypic responses to different therapeutic agents \[[@mdz141-B32]\]. One limitation of our study was the lack of sufficient sequencing data to directly compare TMB to response in our cohort of 171 *EGFR* mutant patients treated with ICI. To address this, we employed a separate cohort of 383 *EGFR* mutant cases with sequencing data available in which we found that *EGFR^Δ19^* tumors had substantially fewer non-synonymous mutations compared with *EGFR^L858R^*tumors \[[@mdz141-B35]\] aligning with the immunotherapy response data. At present, it is unclear what is driving the difference in the TMB between these alleles. It is possible that the increased mutation burden in *EGFR^L858R^*tumors reflects the generally more advanced age of patients with *EGFR^L858R^* at diagnosis compared with patients with *EGFR^Δ19^*alterations \[[@mdz141-B36], [@mdz141-B37]\]. This association would suggest that a clock-like mutational process is at play in *EGFR* mutant tumors, but additional studies are needed to validate this hypothesis \[[@mdz141-B38]\]. In addition, recent work has found that p53 alterations are associated with *EGFR* mutant lung cancer with higher TMB possibly suggesting a more genetically unstable and aggressive tumor state \[[@mdz141-B35]\].

We also found that outcomes of patients treated with ICIs were not affected by *EGFR^T790M^* status or PD-L1 expression levels before immunotherapy. Although we found that fewer prior lines of therapy were associated with increased response to ICI, we unequivocally support the guidance that EGFR TKIs should be the preferred first line treatment option for patients with *EGFR* mutant lung cancer (irrespective of TMB or PD-L1). This guidance is based on substantially higher response rates to EGFR TKIs, the overall low rates of response to PD-(L)1 blockade in this subset of lung cancer, lack of efficacy of PD-L1 blockade in PD-L1+, TKI naïve, *EGFR* mutant lung cancer \[[@mdz141-B16]\], and risk of synergistic toxicity with initial PD-1 blockade followed by osimertinib \[[@mdz141-B39], [@mdz141-B40]\].

This study combined data from multiple institutions, which has advantages and disadvantages. A major advantage is that by pooling data we were able to examine a larger cohort than we would have done individually; however, there is also heterogeneity in the analytical tools used at different institutions, although we aimed to normalize data to the size of the exome sequenced. Another possible limitation of this study was the inclusion of cases treated with different single agent ICIs \[e.g. PD-1 (*n* = 140) and PD-L1 (*n* = 15)\] or combinations of ICIs \[e.g. PD-1 + CTLA-4 (*n* = 15) or PD-L1 + CTLA-4 (*n* = 1)\]. It is possible that these treatment subsets might display unique survival outcomes that are masked by combining the cases.

In summary, our analysis revealed that *EGFR* mutant tumors have differing responses to ICIs and underlying molecular profiles. These data serve as a foundation for further investigating which patients with *EGFR* mutant disease have a higher likelihood of benefitting from immunotherapies, in particular when combined with chemotherapy or antiangiogenesis agents. Studies in animal models of *EGFR* mutant lung cancer with varying baseline mutations and TMB will also be valuable tools for evaluating such approaches. More broadly, our data provide rationale for evaluating genomic and molecular subsets within tumor types with lower TMB to better understand which features are associated with successful outcomes with ICIs.
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